Longer Persistence Seen With Upadacitinib Versus TNFi in Rheumatoid Arthritis

Upatinib is a prescription drug that targets Janus kinase (JAK). In August 2021, it was approved for expanded indications in the European Union and Japan. It should be used in strict accordance with your doctor's instructions.

Upatinib is an oral, once-daily, selective, reversible JAK inhibitor that has played a crucial role in the pathophysiological treatment of various inflammatory diseases, particularly in the treatment of adult patients with moderate to severe rheumatoid arthritis who have not responded to or cannot tolerate methotrexate. In August 2019, utpatinib was approved in the United States for the treatment of rheumatoid arthritis. Other indications under investigation include atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, and ulcerative colitis. In the European Union, utpatinib has been approved for the treatment of rheumatoid arthritis, active psoriatic arthritis, and active ankylosing spondylitis.